INS and pancreatic adenocarcinoma: SHIP1 has been shown to be a promoter with higher activity than that of endogenous human insulin promoters and rat insulin promoters (RIP), which are used to direct expression in pancreatic adenocarcinoma that overexpresses pancreas and duodenal Homeobox gene 1 (PDX-1) (10, 161).